Kliniken Essen-Mitte


Hospital

Location:
Essen, Germany


Publications in cooperation with FAU scientists


Go to first page Go to previous page 1 of 3 Go to next page Go to last page
Mayer, I.A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M.,... Arteaga, C.L. (2019). A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB). Clinical Cancer Research, 25(10), 2975-2987. https://dx.doi.org/10.1158/1078-0432.CCR-18-3160
Wunderle, M., Pretscher, J., Brucker, S.Y., Volz, B., Hartmann, A., Fiessler, C.,... Rauh, C. (2019). Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 174(2), 453-461. https://dx.doi.org/10.1007/s10549-018-05115-6
Denkert, C., Budczies, J., Regan, M.M., Loibl, S., Dell’Orto, P., von Minckwitz, G.,... Viale, G. (2019). Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Research and Treatment. https://dx.doi.org/10.1007/s10549-018-05112-9
Laakmann, E., Witzel, I., Fasching, P., Rezai, M., Schem, C., Solbach, C.,... Loibl, S. (2019). Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Research, 21(1). https://dx.doi.org/10.1186/s13058-019-1144-x
Buckley, M.A., Woods, N.T., Tyrer, J.P., Mendoza-Fandino, G., Lawrenson, K., Hazelett, D.J.,... Freedman, M.L. (2019). Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-17-3864
Schneeweiss, A., Moebus, V., Tesch, H., Hanusch, C., Denkert, C., Luebbe, K.,... Loibl, S. (2019). Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial. European journal of cancer, 106, 181-192. https://dx.doi.org/10.1016/j.ejca.2018.10.015
Polterauer, S., Schwameis, R., Grimm, C., Hillemanns, P., Jückstock, J., Hilpert, F.,... Mahner, S. (2019). Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. Gynecologic Oncology, 153(2), 286-291. https://dx.doi.org/10.1016/j.ygyno.2019.02.007
Lux, M.P., Nabieva, N., Hildebrandt, T., Rebscher, H., Kummel, S., Blohmer, J.-U., & Schrauder, M.G. (2018). Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany. BREAST , 37, 89-98. https://dx.doi.org/10.1016/j.breast.2017.11.002
Cao, J., Wiesweg, M., Fuchs, M., Stein, A., Karthaus, M., Lettmaier, S.,... Kasper, S. (2018). Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf (R)) in patients with metastatic colorectal cancer (CRC) in clinical-routine use. (pp. 289-289).
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C.,... Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). In ANNALS OF ONCOLOGY (pp. 60-60). Munich, DE: OXFORD: OXFORD UNIV PRESS.
Loibl, S., Weber, K., Huober, J., Krappmann, K., Marme, F., Schem, C.,... Denkert, C. (2018). Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research, 24(14), 3358-3365. https://dx.doi.org/10.1158/1078-0432.CCR-17-2947
Kelemen, L.E., Earp, M., Fridley, B.L., Chenevix-Trench, G., Fasching, P.A., Beckmann, M.,... Berchuck, A. (2018). rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 19(9). https://dx.doi.org/10.3390/ijms19092473
Denkert, C., Von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B.I., Weber, K.E.,... Loibl, S. (2018). Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, 19(1), 40-50. https://dx.doi.org/10.1016/S1470-2045(17)30904-X
Glubb, D.M., Johnatty, S.E., Quinn, M.C.J., O'Mara, T.A., Tyrer, J.P., Gao, B.,... Chenevix-Trench, G. (2017). Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 8(39), 64670-64684. https://dx.doi.org/10.18632/oncotarget.18501
Harbeck, N., Saupe, S., Jaeger, E., Schmidt, M., Kreienberg, R., Mueller, L.,... Al-Batran, S.-E. (2017). A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Research and Treatment, 161(1), 63-72. https://dx.doi.org/10.1007/s10549-016-4033-3
Kuemmel, S., Jackisch, C., Mueller, V., Schneeweiss, A., Klawitter, S., & Lux, M.P. (2017). Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit?.
Lux, M.P., Schrauder, M.G., Hildebrandt, T., Nabieva, N., Kuemmel, S., & Blohmer, J.-U. (2017). Comparative budget impact assessment of the different breast cancer genomic tests in Germany. (pp. S102-S103).
Kar, S.P., Adler, E., Tyrer, J., Hazelett, D., Anton-Culver, H., Bandera, E.V.,... Lawrenson, K. (2017). Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), 524-535. https://dx.doi.org/10.1038/bjc.2016.426
Kuemmel, S., & Hack, C. (2017). Event Announcement 3rd Symposium of the AGO Commission Integrative Medicine: "Integrative Medicine: Holistic Care with Natural Healing Procedures". Geburtshilfe und Frauenheilkunde, 77(8), 853-853.
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kroeber, S., Schneeweiss, A.,... Schmutzler, R.K. (2017). Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncology, 3(10), 1378-1385. https://dx.doi.org/10.1001/jamaoncol.2017.1007

Last updated on 2016-10-05 at 08:26